ada glp 1 recommendations standards of care 2025 obesity pharmacotherapy glp-1 When to use for obesity: guidelines ADA 2015 Guidelines, Part 3

This approach assessed persistence versus switching among those active in both months, and therefore, did not evaluate discontinuation (no fill in the subsequent month)

According to Leerink analyst David Reisinger, retatrutide showed higher gastrointestinal side effects than Zepbound, as expected, plus much higher rates of dysesthesia. William Blairs Andy Shea acknowledged that the placebo-adjusted weight loss compares favourably to the 18% figure for Zepbound but predicted the drug will likely be limited to individuals at the higher end of the BMI spectrum. In plain terms: retatrutide works spectacularly, but its probably too punishing for routine use

PMID: 19393193

NRF2 and cancer NRF2 is frequently mutated in many types of cancers, with the mutations clustered around the DLG (43 %) and ETGE (57 %) motifs, which are the two critical KEAP1 interaction domains [95]